{
  "id": "b0d3729c-a6fb-4383-9e58-bbdb178a42e6",
  "title": "Sun Pharma to invest $25 million in Pharmazz Inc; raises stake to 22.7%",
  "link": "https://www.business-standard.com/companies/news/sun-pharma-pharmazz-investment-stake-increase-biopharma-drugs-125052301847_1.html",
  "description": "The company noted that the initial $10 million tranche, along with $7.5 million from the second SAFE tranche, will be invested by or before May 31, 2025",
  "author": "",
  "published": "Fri, 23 May 2025 23:23:12 +0530",
  "source": "https://www.business-standard.com/rss/home_page_top_stories.rss",
  "categories": null,
  "byline": "Himanshu Thakur",
  "length": 2423,
  "excerpt": "Sun Pharma to invest $25 million in Pharmazz Inc, raising its stake to 22.7%. The deal unlocks licensing options for stroke and shock therapies in developed markets.",
  "siteName": "Business Standard",
  "favicon": "https://www.business-standard.com/android-chrome-192x192-min.png",
  "text": "The company noted that the initial $10 million tranche, along with $7.5 million from the second SAFE tranche, will be invested by or before May 31, 2025Pharmazz reported consolidated revenues of $3 million in FY24, up from $0.9 million each in FY23 and FY22. (Photo: Reuters)Himanshu Thakur New Delhi 2 min read Last Updated : May 23 2025 | 11:23 PM ISTListen to This Article Sun Pharmaceutical Industries Ltd on Friday announced it will invest up to $25 million in US-based Pharmazz Inc, increasing its total stake in the biopharmaceutical company to 22.7 per cent. The investment, priced at $5.88925 per share in cash, will also trigger the conversion of an earlier Simple Agreement for Future Equity (SAFE) investment at a 20 per cent discount, translating to a conversion price of $4.7114 per share, the company said in a stock exchange filing. Sun Pharma stated that $10 million from the fresh investment, along with $7.5 million from the second SAFE tranche, will be infused by or before May 31, 2025. The remaining $15 million is expected to be invested by or before November 30, 2025, or on another mutually agreed date. Both drugs have been approved in India and are marketed via partners under the brand names Tyvalzi (Sovateltide) and Lyfaquin (Centhaquine). Sun Pharma currently holds exclusive rights to license and distribute Sovateltide in select emerging markets. Following this latest investment, the company will also gain the option to negotiate licensing rights for Sovateltide in certain developed countries.Also Read Pharmazz has received US FDA approval to conduct Phase-3 Investigational New Drug (IND) trials for both drugs. Notably, Sovateltide has also secured a Special Protocol Assessment (SPA) from the FDA, outlining a defined regulatory pathway. The company plans to initiate global Phase-3 trials to pursue approvals in the US and other international markets. Pharmazz reported consolidated revenues of $3 million in FY24, up from $0.9 million each in FY23 and FY22. Pharmazz portfolio and market strategy Pharmazz Inc is a clinical-stage biopharmaceutical company focused on two drug candidates: Sovateltide, for the treatment of acute cerebral ischemic stroke Centhaquine, for treating hypovolemic shock More From This SectionDon't miss the most important news and views of the day. Get them on our Telegram channelFirst Published: May 23 2025 | 11:23 PM IST",
  "image": "https://bsmedia.business-standard.com/_media/bs/img/article/2025-03/11/thumb/fitandfill/1200X630/1741674040-3678.JPG",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv\u003e\u003ch2\u003eThe company noted that the initial $10 million tranche, along with $7.5 million from the second SAFE tranche, will be invested by or before May 31, 2025\u003c/h2\u003e\u003cdiv\u003e\u003cdiv\u003e\u003cp\u003e\u003ci\u003e\u003c/i\u003e\u003cimg src=\"https://bsmedia.business-standard.com/_media/bs/img/article/2025-03/11/full/1741674040-3678.JPG?im=FitAndFill=(826,465)\" title=\"Sun Pharma\" alt=\"Sun Pharma\" width=\"826\" height=\"465\"/\u003e\u003c/p\u003e\u003c/div\u003e\u003cp\u003ePharmazz reported consolidated revenues of $3 million in FY24, up from $0.9 million each in FY23 and FY22.  (Photo: Reuters)\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cspan\u003e\u003ca href=\"https://www.business-standard.com/author/himanshu-thakur\"\u003e\u003cspan\u003eHimanshu Thakur\u003c/span\u003e\u003c/a\u003e\u003cspan\u003e New Delhi \u003c/span\u003e\u003c/span\u003e\u003c/p\u003e\u003cdiv\u003e\u003cp\u003e2 min read  Last Updated : May 23 2025 | 11:23 PM IST\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003ch4\u003eListen to This Article\u003c/h4\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv id=\"parent_top_div\"\u003e\u003cp\u003e\n\tSun Pharmaceutical Industries Ltd on Friday announced it will invest up to $25 million in US-based Pharmazz Inc, increasing its total stake in the biopharmaceutical company to 22.7 per cent.\u003c/p\u003e\n\u003cp\u003e\n\tThe investment, priced at $5.88925 per share in cash, will also trigger the conversion of an earlier Simple Agreement for Future Equity (SAFE) investment at a 20 per cent discount, translating to a conversion price of $4.7114 per share, the company said in a stock exchange filing.\u003c/p\u003e\n\u003cp\u003e\n\tSun Pharma stated that $10 million from the fresh investment, along with $7.5 million from the second SAFE tranche, will be infused by or before May 31, 2025. The remaining $15 million is expected to be invested by or before November 30, 2025, or on another mutually agreed date.\u003c/p\u003e\n\u003cp\u003e\n\tBoth drugs have been approved in India and are marketed via partners under the brand names Tyvalzi (Sovateltide) and Lyfaquin (Centhaquine).\u003c/p\u003e\n\u003cp\u003e\n\tSun Pharma currently holds exclusive rights to license and distribute Sovateltide in select emerging markets. Following this latest investment, the company will also gain the option to negotiate licensing rights for Sovateltide in certain developed countries.\u003c/p\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3\u003e\u003cspan\u003eAlso Read\u003c/span\u003e\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\n\u003cp\u003e\n\tPharmazz has received US FDA approval to conduct Phase-3 Investigational New Drug (IND) trials for both drugs. Notably, Sovateltide has also secured a Special Protocol Assessment (SPA) from the FDA, outlining a defined regulatory pathway. The company plans to initiate global Phase-3 trials to pursue approvals in the US and other international markets.\u003c/p\u003e\n\u003cdiv\u003e\u003cp\u003e\n\tPharmazz reported consolidated revenues of $3 million in FY24, up from $0.9 million each in FY23 and FY22.\u003csmall\u003e \u003c/small\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003ePharmazz portfolio and market strategy\u003c/strong\u003e\u003c/p\u003e\n\t\u003cp\u003e\n\t\tPharmazz Inc is a clinical-stage biopharmaceutical company focused on two drug candidates:\u003c/p\u003e\n\t\u003cp\u003e\n\t\tSovateltide, for the treatment of acute cerebral ischemic stroke\u003c/p\u003e\n\t\u003cp\u003e\n\t\tCenthaquine, for treating hypovolemic shock\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3\u003e\u003cspan\u003eMore From This Section\u003c/span\u003e\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cp\u003e\u003ca href=\"https://t.me/bsindiaofficial\" target=\"_blank\"\u003eDon\u0026#39;t miss the most important news and views of the day. Get them on our  \u003csvg style=\"margin:0px 4px 0px 6px;transform:translate(-1px, 5px)\" width=\"20\" height=\"20\" viewBox=\"0 0 32 32\" fill=\"none\" xmlns=\"http://www.w3.org/2000/svg\"\u003e\u003ccircle cx=\"16\" cy=\"16\" r=\"16\" fill=\"#22A7E9\"\u003e\u003c/circle\u003e\u003cpath fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M21.3427 10.0889C21.5394 10.0102 21.7547 9.98303 21.9662 10.0103C22.1777 10.0375 22.3777 10.1182 22.5453 10.2439C22.7129 10.3696 22.842 10.5357 22.9192 10.725C22.9964 10.9143 23.0188 11.1197 22.9842 11.32L21.1787 21.736C21.0035 22.7407 19.8445 23.3169 18.8757 22.8164C18.0653 22.3977 16.8616 21.7526 15.779 21.0795C15.2376 20.7426 13.5794 19.6637 13.7832 18.8959C13.9583 18.2395 16.7446 15.7728 18.3367 14.3062C18.9616 13.73 18.6766 13.3976 17.9387 13.9276C16.1053 15.2435 13.1639 17.2446 12.1911 17.8079C11.3329 18.3046 10.8855 18.3894 10.3506 18.3046C9.37458 18.1502 8.46945 17.9109 7.7307 17.6194C6.73243 17.2257 6.78099 15.9204 7.72991 15.5403L21.3427 10.0889Z\" fill=\"white\"\u003e\u003c/path\u003e\u003c/svg\u003e Telegram channel\u003c/a\u003e\u003c/p\u003e\u003cp\u003eFirst Published: May 23 2025 | 11:23 PM IST\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "3 min read",
  "publishedTime": "2025-05-23T23:23:11+05:30",
  "modifiedTime": null
}
